Real-world data reveal coronavirus jab effectiveness for young people

20 October 2021

Results from a Centers for Disease Control and Prevention (CDC) trial of Comirnaty, the coronavirus vaccine developed by Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX), show a high level of effectiveness at preventing hospitalizations among adolescents.

Among hospitalized COVID-19 patients in the USA aged 12–18 years, 97% had not been vaccinated, the study found.

The findings are consistent with efficacy data from the Pfizer-BioNTech clinical trial program in this age group, which found vaccine efficacy of 100%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK